Invasive Breast Cancer
Conditions
Brief summary
This is a prospective, single-center, non-randomized, non-controlled study
Detailed description
Immunotherapy with immune-checkpoint inhibitors (ICIs) has enabled a leap forward in the treatment of various types of cancer within the past decade. However,only 12.46% of patients with cancer are expected to respond to ICIs.Our team have recently developed a multi-specific antibody technology platform for the microenvironment of solid tumors. In this study, we are going to study the tumor immune microenvironment of breast cancer patients by patient-derived organoids or PDX model，to design multi-specific antibody drugs for different tumor immune microenvironment，to look forward to improve the effectiveness of immunotherapy for breast cancer and solve the problem of drug resistance.
Interventions
None listed
Sponsors
Peking University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Women between 18 and 70 years old； 2. Primary lesion \>2cm on imaging examination, or suspected axillary lymph node metastasis on imaging examination； 3. Previous not received preoperative radiotherapy, chemotherapy, endocrine therapy, immunotherapy, or other anticancer treatments； 4. Subjects signed informed consent；
Exclusion criteria
1. A history of prior or concomitant malignancies; 2. Advanced stage breast cancer (stage IV)； 3. Suspected or confirmed lesion was surgically removed； 4. Patients were accompanied by severe organic diseases such as heart and cerebral disease, and liver and kidney disease.；
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| antitumor rate of multi-specific antibody in patient-derived organoids and PDX model | 24 months | Patient-derived organoids and PDX model |
Countries
China
Contacts
Primary ContactZhaoqing Fan, MD
Outcome results
None listed